FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Cormorant Asset Management, LP		 2. Date of Event Requiring Statement (MM/DD/YYYY)
3/3/2023 

 3. Issuer Name and Ticker or Trading Symbol

Ambrx Biopharma Inc. [AMAM]
(Last)        (First)        (Middle)

200 CLARENDON STREET, 52ND FLOOR		 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          ___X___ 10% Owner
_____ Officer (give title below)        _____ Other (specify below)
(Street)

BOSTON, MA 02116      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		2. Amount of Securities Beneficially Owned
(Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Ordinary Shares 52500000 I See Footnotes (1)(2)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
(1) Information reported herein relates to ordinary shares represented by American Depository Shares owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and Cormorant Private Healthcare Fund III, LP ("Fund III"), 42,771,365 of which ordinary shares are beneficially owned by the Master Fund and 9,728,635 of which ordinary shares are beneficially owned by Fund III.
(2) Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund and Fund III. Cormorant Global Healthcare GP, LLC ("GP LLC") and Cormorant Private Healthcare GP III, LLC ("GP III") serve as General Partner of the Master Fund and Fund III, respectively. Bihua Chen serves as manager of Cormorant, GP LLC and GP III. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 3 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Cormorant Asset Management, LP
200 CLARENDON STREET
52ND FLOOR
BOSTON, MA 02116
X

Cormorant Global Healthcare Master Fund, LP
200 CLARENDON STREET
52ND FLOOR
BOSTON, MA 02116
X

Cormorant Private Healthcare Fund III LP
200 CLARENDON STREET
52ND FLOOR
BOSTON, MA 02116
X

Chen Bihua
C/O CORMORANT ASSET MANAGEMENT, LP
200 CLARENDON STREET, 52ND FLOOR
BOSTON, MA 02116
X
Signatures
/s/ CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP, By: Cormorant Global Healthcare GP, LLC, its General Partner, By: Bihua Chen, Managing Member3/13/2023
**Signature of Reporting PersonDate

/s/ CORMORANT PRIVATE HEALTHCARE FUND III, LP, By: Cormorant Private Healthcare GP III, LLC, its General Partner, By: Bihua Chen, Managing Member3/13/2023
**Signature of Reporting PersonDate

/s/ CORMORANT ASSET MANAGEMENT, LP, By: Cormorant Asset Management GP, LLC, its General Partner, By: Bihua Chen, Managing Member3/13/2023
**Signature of Reporting PersonDate

/s/ Bihua Chen3/13/2023
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Ambrx Biopharma (NYSE:AMAM)
Historical Stock Chart
Von Mär 2024 bis Apr 2024 Click Here for more Ambrx Biopharma Charts.
Ambrx Biopharma (NYSE:AMAM)
Historical Stock Chart
Von Apr 2023 bis Apr 2024 Click Here for more Ambrx Biopharma Charts.